Tamibarotene是一种具有口服活性的合成维甲酸，旨在克服全反式维甲酸耐药性，具有潜在的抗肿瘤活性。它也是视黄酸受体α/β 的激动剂，比RARγ的选择性高。

Tamibarotene is an orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity.

Tamibarotene治疗明显降低小鼠的脑中不溶性Aβ水平,特别是Aβ（42）,而Tamibarotene对可溶性Aβ水平没有明显影响.

Tamibarotene诱导的HL-60细胞粘附到内皮细胞比全反式维甲酸低38％,Tamibarotene诱导NB4细胞粘附到内皮细胞的能力和ATRA相当,其在HL-60中两相诱导CD38基因转录细胞,通过含有内含子1的DR-RARE的早期相诱导和通过缺乏5'侧翼区的RARE的延迟相诱导。Tamibarotene仅诱导HL-60细胞的早期诱导,导致比ATRA低的CD38诱导。Tamibarotene对外周血单核细胞的生长抑制可以忽略不计,但对HTLV-I感染T细胞系和ATL细胞的标记的生长抑制很强。Tamibarotene使HTLV-I感染T细胞系细胞停留在细胞周期的G1期,并诱导细胞凋亡。Tamibarotene也抑制IkappaBalpha的磷酸化和NF-κB-DNA结合,并减少参与G1/S期细胞周期的过渡和凋亡蛋白表达。Tamibarotene也抑制JunD的表达,从而抑制AP-1的DNA结合。Tamibarotene略微抑制了骨髓瘤细胞和HUVEC的生长,并显着抑制由VEGF刺激的HUVEC的生长。Tamibarotene显示对骨髓基质细胞（BMSC）的生长抑制很小,但通过共培养骨髓瘤细胞显着抑制HUVEC的迁移。Tamibarotene抑制VEGF诱导的VEGF受体的磷酸化。Tamibarotene明显抑制小鼠角膜中VEGF诱导的体外管样结构的形成和新生血管的形成。

The CellTiter Aqueous Non-Radioactive Cell Proliferation Assay Kit is used to assess cell growth. Briefly, 10,000 cells per well are seeded in a 96-well plate and cultured in RPMI containing 2% charcoal-stripped FBS and indicated retinoid concentrations for 72 hours. At the end of the treatment period, the MTS reagent is added, cells are incubated an additional 2-4 hours, and absorbance is measured at 490 nanometers.

94497-51-5

C22H25NO3

351.446

Amnolake;Am 80;他米巴罗汀;NSC 608000

1.1eq. NaOH:35.1 mg/mL (100 mM)
DMSO:17.6 mg/mL (50 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years